Practical considerations in the use of regorafenib in metastatic colorectal cancer.

Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325

Chiara Cremolini, Marta Schirripa, Carlotta Antoniotti, Roberto Moretto, Lisa Salvatore, Gianluca Masi, Alfredo Falcone, Fotios Loupakis, First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nature Reviews Clinical Oncology. ,vol. 12, pp. 607- 619 ,(2015) , 10.1038/NRCLINONC.2015.129

Ralf-Dieter Hofheinz, Dirk Arnold, Stefan Kubicka, Nicole Prasnikar, Arndt Vogel, Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Onkologie. ,vol. 38, pp. 300- 308 ,(2015) , 10.1159/000382067

Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864

Mieke De Wit, Christine B. Boers-Doets, Alessandra Saettini, Kristina Vermeersch, Carmen Roncero de Juan, Jan Ouwerkerk, See-See Raynard, Ashley Bazin, Chiara Cremolini, Prevention and management of adverse events related to regorafenib Supportive Care in Cancer. ,vol. 22, pp. 837- 846 ,(2014) , 10.1007/S00520-013-2085-Z

A. Hendlisz, A. Deleporte, C. Vandeputte, N. Charette, M. Paesmans, T. Guiot, C. Garcia, P. Flamen, Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol BMJ Open. ,vol. 5, ,(2015) , 10.1136/BMJOPEN-2014-007189

Lotfi Abou-Elkacem, Susanne Arns, Gunnar Brix, Felix Gremse, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model Molecular Cancer Therapeutics. ,vol. 12, pp. 1322- 1331 ,(2013) , 10.1158/1535-7163.MCT-12-1162

Jin Li, Shukui Qin, Ruihua Xu, Thomas C C Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun-Huei Yeh, Feng Bi, Ying Cheng, Anh Tuan Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, Joachim Kalmus, Tae Won Kim, Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncology. ,vol. 16, pp. 619- 629 ,(2015) , 10.1016/S1470-2045(15)70156-7

B. McLellan, F. Ciardiello, M.E. Lacouture, S. Segaert, E. Van Cutsem, Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management Annals of Oncology. ,vol. 26, pp. 2017- 2026 ,(2015) , 10.1093/ANNONC/MDV244

Axel Grothey, Suzanne George, Eric Cutsem, Jean‐Yves Blay, Alberto Sobrero, George D. Demetri, Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care Oncologist. ,vol. 19, pp. 669- 680 ,(2014) , 10.1634/THEONCOLOGIST.2013-0059